ReviewFrontiers in medicine2021
What's New in the Treatment of Systemic Lupus Erythematosus.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- What's New in Cutaneous Lupus Erythematosus: Guidelines, Biologics, and Beyond.The Journal of clinical and aesthetic dermatology · 2026Review
- B-cell subset changes and clinical predictors of telitacicept response in SLE patients with antiphospholipid antibody positivity: a prospective observational cohort study.Frontiers in immunology · 2026Observational
- Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of ≥ 10 years: a real-world evidence study.Rheumatology international · 2025Article
- Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.Zeitschrift fur Rheumatologie · 2024Article
- Systemic Lupus Erythematosus: How Machine Learning Can Help Distinguish between Infections and Flares.Bioengineering (Basel, Switzerland) · 2024Article
- A Review of the Potential Benefits of Herbal Medicines, Small Molecules of Natural Sources, and Supplements for Health Promotion in Lupus Conditions.Life (Basel, Switzerland) · 2023Review
- Improving resource utilisation in SLE drug development through innovative trial design.Lupus science & medicine · 2023Review
- Clinical analysis of patients with systemic lupus erythematosus complicated with liver failure.Clinical rheumatology · 2023Article
- Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.Human vaccines & immunotherapeutics · 2022Review
- Development of therapeutic antibodies for the treatment of diseases.Molecular biomedicine · 2022Review
- Understanding Ocular Findings and Manifestations of Systemic Lupus Erythematosus: Update Review of the Literature.International journal of molecular sciences · 2022Review
- Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.International journal of molecular sciences · 2022Review
- Sexual Dimorphisms of Protein-Coding Gene Profiles in Placentas From Women With Systemic Lupus Erythematosus.Frontiers in medicine · 2022Article
- Association of concomitant autoimmunity with the disease features and long-term treatment and health outcomes in Celiac disease.Frontiers in medicine · 2022Article
- Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.Journal of translational autoimmunity · 2022Article
- Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.Journal of neuroinflammation · 2021Review
- Telitacicept: First Approval.Drugs · 2021Review
- Lupus Academy: Keeping Education Live, Virtually.Journal of European CME · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease with a variable presentation and manifestations ranging from mild to severe or even life-threatening. There is an ongoing and unmet need for novel, disease-specific, effective and safe treatment modalities. The aim of this review is to summarize data on SLE treatment that have emerged over the last 3 years. We will put emphasis on studies evaluating potential treatments on severe lupus manifestations such as lupus nephritis. Despite the existence of several therapeutic agents in SLE, the disease keeps causing significant morbidity. It is encouraging that a variety of therapeutic options are currently under investigation, although there are occasional trial failures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.